Page last updated: 2024-12-10

1-[[2-(2,4-dichlorophenoxy)-1-oxoethyl]amino]-3-(4-methoxyphenyl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-[[2-(2,4-dichlorophenoxy)-1-oxoethyl]amino]-3-(4-methoxyphenyl)thiourea is a complex chemical compound with the following characteristics:

* **Structure:** The compound is a thiourea derivative, meaning it contains a thiourea group (-NH-CS-NH-). This group is attached to a 4-methoxyphenyl group and a modified phenoxy group.
* **Properties:** The compound likely exhibits specific physical and chemical properties due to its structure, including potential solubility, melting point, and reactivity.

**Importance for research:**

The importance of this compound for research lies in its potential applications, which are likely related to its specific structure and properties. Some possible areas of interest include:

* **Herbicidal activity:** The presence of the 2,4-dichlorophenoxy group suggests a potential link to herbicides. This group is a common motif in herbicides, targeting plant growth regulators. Further investigation could reveal if this compound exhibits herbicidal activity and its mechanism of action.
* **Pharmacological activity:** Thiourea derivatives are known to possess a range of pharmacological activities, such as anti-inflammatory, antioxidant, and antimicrobial effects. This specific compound could be investigated for its potential therapeutic properties.
* **Material science:** The compound might possess unique properties relevant to material science. For instance, its ability to form crystals or its interactions with specific materials could be investigated for potential applications in areas like organic electronics or advanced materials.

**Research implications:**

Research involving 1-[[2-(2,4-dichlorophenoxy)-1-oxoethyl]amino]-3-(4-methoxyphenyl)thiourea could contribute to:

* **Development of new herbicides:** Understanding its herbicidal activity could lead to the development of more efficient and environmentally friendly herbicides.
* **Discovery of new drugs:** Investigating its pharmacological properties could reveal potential therapeutic uses for treating various diseases.
* **Creation of innovative materials:** Its unique properties could contribute to the development of advanced materials with specific applications in different fields.

**Note:** It's important to emphasize that this information is based on the compound's structure and potential applications derived from similar compounds. Further research is necessary to determine the specific properties and applications of this particular compound.

Cross-References

ID SourceID
PubMed CID4128012
CHEMBL ID1428238
CHEBI ID109394

Synonyms (21)

Synonym
smr000236375
MLS000722976
CHEBI:109394
AKOS005109756
1-[[2-(2,4-dichlorophenoxy)acetyl]amino]-3-(4-methoxyphenyl)thiourea
AKOS003624701
HMS2558P11
STL282423
2-[(2,4-dichlorophenoxy)acetyl]-n-(4-methoxyphenyl)hydrazinecarbothioamide
1-(2-(2,4-dichlorophenoxy)acetyl)-4-(4-methoxyphenyl)thiosemicarbazide
69026-42-2
F0807-0307
(e)-2-(2-(2,4-dichlorophenoxy)acetyl)-n-(4-methoxyphenyl)hydrazinecarbimidothioic acid
2-(2,4-dichlorophenoxy)-n-{[(4-methoxyphenyl)carbamothioyl]amino}acetamide
MS-7596
CHEMBL1428238
1-[[2-(2,4-dichlorophenoxy)-1-oxoethyl]amino]-3-(4-methoxyphenyl)thiourea
Q27188513
mfcd00955347
2-(2-(2,4-dichlorophenoxy)acetyl)-n-(4-methoxyphenyl)hydrazinecarbothioamide
2-(2,4-dichlorophenoxy)-n-{[(e)-(4-methoxyphenyl)thio(carbonoimidyl)]amino}acetamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
substituted aniline
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency70.79460.631035.7641100.0000AID504339
thioredoxin reductaseRattus norvegicus (Norway rat)Potency15.84890.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686978; AID686979
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency4.46680.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency2.23870.039816.784239.8107AID1454
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.78280.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.00460.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency8.91250.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency1.41250.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]